# AstraZeneca’s Farxiga receives US approval from FDA for use with chronic kidney disease

- Link: https://www.directorstalkinterviews.com/astrazenecas-farxiga-receives-us-approval-from-fda-for-use-with-chronic-kidney-disease/412984797
- Published: 2021-05-04T07:27:52+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Farxiga_ (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has
been approved in the US to reduce the risk of sustained estimated glomerular filtration
rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular death and hospitalisation
for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression.

The approval by the Food and Drug Administration (FDA) was based on positive results
from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation
granted by the FDA earlier this year.

CKD, a condition defined by decreased kidney function, is often associated with 
a heightened risk of heart disease or stroke, or the need for dialysis or kidney
transplant.^(1-3) CKD is expected to become the fifth leading cause of mortality
globally by 2040.^(4) Currently in the US, 37 million people are estimated to have
CKD.^(1)

> **The co-chair of the DAPA-CKD trial and its executive committee, Prof. Hiddo 
> L. Heerspink, University Medical Center Groningen, the Netherlands, said**: “Based
> on the unprecedented results of the DAPA-CKD trial, dapagliflozin is now the first
> SGLT2 inhibitor approved for the treatment of chronic kidney disease regardless
> of diabetes status. This transformational milestone provides patients and physicians
> with a new and effective treatment option for this often debilitating and life-
> threatening disease.”

> **Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said:** “Today’s
> approval is the most significant advancement in the treatment of chronic kidney
> disease in more than 20 years. We’ve shown impressive efficacy for _Farxiga_ in
> type-2 diabetes, heart failure with reduced ejection fraction and, most recently,
> chronic kidney disease and we are thrilled to be able to bring this medicine to
> millions of patients in the US.”

The DAPA-CKD trial demonstrated that _Farxiga_, on top of standard-of-care treatment
with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker,
reduced the relative risk of worsening of renal function, onset of ESKD, or risk
of CV or renal death by 39%, the primary composite endpoint, compared to placebo(
p<0.0001) in patients with CKD Stages 2-4 and elevated urinary albumin excretion.
The absolute risk reduction (ARR) was 5.3% over the median time in study of 2.4 
years. _Farxiga_ also significantly reduced the relative risk of death from any 
cause by 31% (ARR=2.1%, p=0.0035) compared to placebo.^(5)

Exploratory analyses of the DECLARE-TIMI 58 Phase III trial, a randomised, double-
blind, placebo-controlled trial, conducted to determine the effect of _Farxiga_ 
on CV outcomes support the conclusion that _Farxiga_ is also likely to be effective
in patients with less advanced CKD. _Farxiga_ is not recommended for the treatment
of CKD in patients with polycystic kidney disease or patients requiring or with 
a recent history of immunosuppressive therapy for kidney disease, since it is not
expected to be effective in these populations.

In both trials, the safety and tolerability of _Farxiga_ were consistent with the
well-established safety profile of the medicine.

In the US, _Farxiga_ is indicated as an adjunct to diet and exercise to improve 
glycaemic control in adults with type-2 diabetes (T2D), and to reduce the risk of
hHF in adults with T2D and established CV disease or multiple CV risk factors. _Farxiga_
is also indicated to reduce the risk of CV death and hHF in adults with heart failure(
NYHA class II-IV) with reduced ejection fraction (HFrEF) with and without T2D.

**Chronic kidney disease** 

CKD is a serious, progressive condition defined by decreased kidney function (shown
by reduced eGFR or markers of kidney damage, or both, for at least three months)
^(3) affecting 840 million people worldwide, many of them still undiagnosed.^(6)
The most common causes of CKD are diabetes, hypertension and glomerulonephritis.
^(7) CKD is associated with significant patient morbidity and an increased risk 
of CV events, such as heart failure (HF) and premature death. In its most severe
form, known as ESKD, kidney damage and deterioration of kidney function have progressed
to the stage where dialysis or kidney transplantation are required.^(1) The majority
of patients with CKD will die from CV causes before reaching ESKD.^(8)

**DAPA-CKD **

DAPA-CKD was an international, multi-centre, randomised, double-blinded Phase III
trial in 4,304 patients designed to evaluate the efficacy of _Farxiga_ 10mg, compared
with placebo, in patients with CKD Stages 2-4 and elevated urinary albumin excretion,
with and without T2D. _Farxiga_ was given once daily in addition to standard of 
care. The primary composite endpoint was worsening of renal function or risk of 
death (defined as a composite of an eGFR decline ≥50%, onset of ESKD or death from
CV or renal cause). The secondary endpoints included the time to first occurrence
of the renal composite (sustained ≥50% eGFR decline, ESKD or renal death), the composite
of CV death or hHF, and death from any cause. The trial was conducted in 21 countries.
^(9 )Detailed results from the trial were published in The New England Journal of
Medicine.^(9)

**DECLARE-TIMI 58**

DECLARE-TIMI 58 was an AstraZeneca-sponsored, randomised, double-blinded, multi-
centre Phase III trial designed to evaluate the effect of _Farxiga_ compared with
placebo on CV outcomes in adults with T2D at risk of CV events, including patients
with multiple CV risk factors or established CV disease, and also assessed key renal
exploratory endpoints. The trial included more than 17,000 patients across 882 sites
in 33 countries and was independently conducted in collaboration with academic investigators
from the TIMI study group (Boston, US) and the Hadassah Hebrew University Medical
Center (Jerusalem, Israel). Results from the trial were published in The Lancet_._
^(10)

Share on:
